Is Brain a Good Journal? Impact Factor, Scope, and Fit Guide

Every major neurology/neuroscience journal occupies a defined lane:

• Lancet Neurology (IF 45.5): Purely clinical. Trials, guidelines, clinical outcomes.
• JAMA Neurology (IF 22.3): Clinical neurology, JAMA-style conciseness, practice relevance.
• Nature Neuroscience (IF 21.2): Basic neuroscience. Circuits, computation, development.
• Neurology (IF 8.3): AAN flagship. Clinical neurology with a broad scope.

Brain (IF 11.7) sits in the gap between these lanes. It publishes deep mechanistic neurology with clinical implications - papers that explain disease biology at the molecular, cellular, or circuit level while keeping one foot firmly in clinical neurology.

This means a paper on alpha-synuclein aggregation that explains why Parkinson's disease progresses in a specific pattern fits Brain. The same protein study without disease relevance fits a basic science journal. A clinical trial in Parkinson's without mechanistic depth fits Lancet Neurology or Neurology.

The editorial test is: does this paper help neurologists understand why a disease works the way it does? Not just what happens, but why.

The journal's highest-impact publications follow a recognizable pattern:

1. Disease question first: the paper opens with a neurological problem, not a molecular observation
2. Mechanistic depth: genetics, pathology, imaging, or functional data that explain the biology of the disease
3. Multi-level evidence: human data anchored by model systems, or clinical observations explained by molecular mechanisms
4. Clinical bridge in the discussion: explicit implications for how neurologists should think about the disease or its treatment
5. Writing for the neurologist-scientist: accessible enough for a clinical reader, rigorous enough for a basic scientist

Brain has particular editorial strength in neurodegenerative diseases - Alzheimer's, Parkinson's, ALS, frontotemporal dementia, prion diseases. This is not the only scope, but it is the area where Brain's bridge identity is most distinctive. Papers that connect genetic risk, protein pathology, circuit dysfunction, and clinical phenotype in neurodegenerative disease are the journal's signature content.

Other areas where Brain is strong: movement disorders, neuroimmunology (especially MS mechanisms), epilepsy genetics, and rare neurological diseases with clear mechanistic insight.

In our pre-submission review work with manuscripts targeting Brain, three patterns generate the most consistent desk rejections among the papers we analyze.

Mechanistic claim present, mechanistic data absent. Brain's editorial guidelines state that papers should "provide novel mechanistic insights into neurological disease." In practice, we see manuscripts that position a finding as mechanistic in the abstract and discussion but rely entirely on association data in the results: GWAS hits, biomarker panels, or cohort-level correlations. Brain editors identify this gap in the first read. If the mechanism is asserted rather than demonstrated, the paper will not clear the desk screen, regardless of sample size or clinical significance.

Clinical bridge missing from basic neuroscience work. A consistent failure pattern: manuscripts with excellent molecular or circuit-level data that never land on clinical neurology. Brain is not a basic neuroscience journal. The data must explain why a neurological disease works the way it does for human patients. Papers that explain alpha-synuclein seeding kinetics in cell culture without connecting to Parkinson's disease progression, clinical variability, or pathological staging will be redirected to a basic science journal. The clinical bridge must be in the data, not only the discussion.

Single-model evidence without validation. Brain's reviewer pool expects mechanistic claims supported across multiple evidence levels: animal models corroborated by human tissue, or clinical observations explained by functional cellular data. In our review work, manuscripts that depend entirely on one mouse model, one patient cohort, or one in vitro system without orthogonal validation consistently receive requests for additional experiments or outright rejections at review. Brain editors anticipate this reviewer response and often decline such papers at the editorial stage.

SciRev author-reported data confirms Brain's 4-6 week median to first decision for papers that clear the initial screen. A Brain mechanistic argument and multi-level evidence check can assess whether your mechanistic argument is strong enough for Brain's editorial standards before you submit.